Lifetime management of severely calcified coronary lesions: the treatment algorithm focused on the shape of calcification.
Sakakura K, Jinnouchi H, Taniguchi Y, Yamamoto K, Fujita H.
Cardiovasc Interv Ther. 2023 Oct;38(4):375-380. doi: 10.1007/s12928-023-00950-x. Epub 2023 Aug 5.
Mid-term clinical outcomes of new generation drug-eluting stents for treatment of diffuse coronary artery disease.
Çoner A, Çiçek D, Akıncı S, Balcıoğlu S, Altın C, Müderrisoğlu H.
Turk Kardiyol Dern Ars. 2018 Dec;46(8):659-666. doi: 10.5543/tkda.2018.10.5543/tkda.2018.62678.
Feasibility and Clinical Outcomes of 48 mm Drug-Eluting Stents in the Management of Patients With Coronary Artery Disease.
El Amrawy AM, Loutfi MI, El Tahan SM, Ayad SW.
J Invasive Cardiol. 2021 Dec;33(12):E960-E967. doi: 10.25270/jic/20.00660. Epub 2021 Nov 24.
Identifying the Incidence, Predictors, Outcomes, and Prevention of Stent Thrombosis (ST) in Post-percutaneous Coronary Revascularization Patients With Drug-Eluting Stents (DES): A Systematic Review.
Sohail M, Patel P, Midha S, Shukla S, Dhamija D, Bello AO, Khan AA, Gutlapalli SD, Venugopal S.
Cureus. 2023 Sep 13;15(9):e45150. doi: 10.7759/cureus.45150. eCollection 2023 Sep.
Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery.
Tsagalou E, Chieffo A, Iakovou I, Ge L, Sangiorgi GM, Corvaja N, Airoldi F, Montorfano M, Michev I, Colombo A.
J Am Coll Cardiol. 2005 May 17;45(10):1570-3. doi: 10.1016/j.jacc.2005.01.049.
Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K, Mehilli J, Byrne RA, Schulz S, Massberg S, Laugwitz KL, Vorpahl M, Seyfarth M, Kastrati A; ISAR-LEFT MAIN Study Investigators.
JACC Cardiovasc Interv. 2014 Jan;7(1):29-36. doi: 10.1016/j.jcin.2013.08.013. Epub 2013 Dec 11.
Current concepts on coronary revascularization in diabetic patients.
Roffi M, Angiolillo DJ, Kappetein AP.
Eur Heart J. 2011 Nov;32(22):2748-57. doi: 10.1093/eurheartj/ehr305. Epub 2011 Sep 4.
Prognostic value of plasma pentraxin-3 levels in patients with stable coronary artery disease after drug-eluting stent implantation.
Haibo L, Xiaofang G, Chunming W, Jie Y, Guozhong C, Limei Z, Yong C, Yu F, Yingchun B, Wangjun Y, Junbo G.
Mediators Inflamm. 2014;2014:963096. doi: 10.1155/2014/963096. Epub 2014 Nov 24.
Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes.
Tamburino C, Di Salvo ME, Capodanno D, Palmerini T, Sheiban I, Margheri M, Vecchi G, Sangiorgi G, Piovaccari G, Bartorelli A, Briguori C, Ardissino D, Di Pede F, Ramondo A, Inglese L, Petronio AS, Bolognese L, Benassi A, Palmieri C, Filippone V, De Servi S.
Am J Cardiol. 2009 Jan 15;103(2):187-93. doi: 10.1016/j.amjcard.2008.08.059. Epub 2008 Oct 30.
Intravascular ultrasound-guided percutaneous coronary intervention improves the clinical outcome in patients undergoing multiple overlapping drug-eluting stents implantation.
Ahn SG, Yoon J, Sung JK, Lee JH, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Lee SH, Choe KH.
Korean Circ J. 2013 Apr;43(4):231-8. doi: 10.4070/kcj.2013.43.4.231. Epub 2013 Apr 30.
